Market: NASD |
Currency: USD
Address: 2215 Yukon Street
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Show more
📈 AbCellera Biologics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$9.33
-
Upside/Downside from Analyst Target:
113.58%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-04
-
EPS Estimate:
-0.16
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for AbCellera Biologics Inc.
| Date | Reported EPS |
|---|
| 2025-11-03 (estimated upcoming) | - |
| 2025-08-07 | -0.12 |
| 2025-05-08 | -0.15 |
| 2025-02-27 | -0.12 |
| 2024-11-04 | -0.17 |
| 2024-08-06 | -0.13 |
| 2024-05-07 | -0.14 |
| 2024-02-20 | -0.16 |
| 2023-11-02 | -0.1 |
| 2023-08-03 | -0.11 |
| 2023-05-04 | -0.14 |
| 2023-02-21 | -0.1 |
| 2022-11-08 | 0.08 |
| 2022-08-09 | -0.02 |
| 2022-05-10 | 0.54 |
| 2022-02-24 | 0.19 |
| 2021-11-09 | -0.08 |
| 2021-08-12 | -0.01 |
| 2021-05-13 | 0.37 |
| 2021-03-29 | 0.37 |
📰 Related News & Research
No related articles found for "abcellera biologics".
